CALDESENE DIAPER RASH TREATMENT SAFETY/EFFICACY STUDIES DISCUSSED
This article was originally published in The Tan Sheet
CALDESENE DIAPER RASH TREATMENT SAFETY/EFFICACY STUDIES DISCUSSED at a Jan. 24 meeting between FDA officials and representatives from Ciba Consumer, which acquired the Caldesene line and other OTCs from Fisons in late 1992. According to an agency memorandum of the meeting, Ciba Consumer requested the session to "determine the overall status and possible need for testing of Caldesene" products containing calcium undecylenate to support claims for diaper rash.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC